Showing 2791-2800 of 4091 results for "".
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Positive Topline Results from Pivotal Phase 3 Trial of Arcutis Biotherapeutics' Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-results-from-pivotal-phase-3-trial-of-arctuis-biotherapeutics-roflumilast-foam-in-scalp-and-body-psoriasis/2461359/Topline results from the ARRECTOR Pivotal Phase 3 trial evaluating Arcutis Biotherapeutics, Inc.'s roflumilast foam 0.3% were positive for the treatment of adults and adolescents with scalp and body psoriasis. The study met its co-primary endpoints of S-
- Rodan + Fields Gives Back: Company Announces More Donations from Youth Empowerment Fundhttps://practicaldermatology.com/news/rodan-fields-gives-back-company-announces-more-donations-from-youth-empowerment-fund/2461300/Rodan + Fields has announced the second round of donations from the Youth Empowerment Fund through their support of the Prescription for Change project. Launched in August 2021, the Fund will invest a total of $5 Million over three years to empower young people to l
- Cynosure Scores $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://practicaldermatology.com/news/cynosure-scores-60-million-follow-on-investment-from-clayton-dubilier-rice/2461199/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its customers that
- New Patient Satisfaction Data from Dermavant's PSOARING 3 Trial of Tapinarof in Adults with Plaque Psoriasishttps://practicaldermatology.com/news/new-patient-satisfaction-data-from-dermavants-psoaring-3-trial-of-tapinarof-in-adults-with-plaque-psoriasis/2461043/Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof
- Dermavant: Promising Interim Analysis from Third Phase 3 Trial for Tapinarof in Psoriasishttps://practicaldermatology.com/news/dermavant-promising-interim-analysis-from-third-phase-3-trial-for-tapinarof-in-psoriasis/2460693/Positive results from a planned interim analysis of PSOARING 3, Dermavant Sciences’ long-term, open-label safety study, show that approximately 40 percent of subjects treated with investigational tapinarof cream, 1% achieved complete disease clearance (PGA score = 0). Treatment was well tol
- People with Severe Atopic Dermatitis May Have Increased Risk of Death from Several Causeshttps://practicaldermatology.com/news/people-with-severe-atopic-dermatitis-may-have-increased-risk-of-death-from-several-causes/2460673/Although there is limited evidence for overall increased mortality in patients with atopic eczema, those with severe atopic eczema may have a greater risk of dying from several health issues compared with those without eczema, according to a new study in the Journal of Allergy and Clinical Im
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Positive Topline Data from Phase 2b Study of Roflumilast Foam for Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-data-from-phase-2b-study-of-roflumilast-foam-for-scalp-and-body-psoriasis/2460633/Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, shared positive top line data from a Phase 2b clinical trial evaluating ARQ-
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s